NCT07599904Recruiting
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Medtronic Neurovascular Clinical Affairs
Start Date
7/13/2026
Completion Date
7/1/2031
Summary
Post-Market Registry
Detailed Description
An observational, prospective, multi-center, single-arm registry to provide continuing evaluation of safety and effectiveness of Medtronic Neurovascular commercially available products used in the treatment of acute ischemic stroke.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements.
2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke.
3. Participant is 18 years of age or older.
Exclusion Criteria:
1. Participant who may be unable to complete follow-up within the registry.
2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.
3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.
Interventions
DEVICE
Mechanical Thrombectomy
Conditions
Acute Ischemic Stroke
Locations
McLaren Flint Hospital
Flint, Michigan 48532
United States
Buffalo General Medical Center
Buffalo, New York 14203
United States
University of Texas Health Science Center at Houston
Houston, Texas 77030
United States